Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + nab-paclitaxel + vismodegib
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen of three drugs used in the treatment of cancer, particularly pancreatic adenocarcinoma. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing cells. Nab-paclitaxel (albumin-bound paclitaxel) stabilizes microtubules and prevents their disassembly, inhibiting mitosis. Vismodegib (GDC-0449) is an oral small-molecule inhibitor of the Hedgehog signaling pathway by antagonizing Smoothened (SMO), thereby blocking downstream signaling involved in tumor growth and maintenance of cancer stem cells. This combination has been investigated for synergistic effects against pancreatic cancer, with studies showing enhanced inhibition of tumor growth compared to standard regimens[1][2].
- Other names
- gemcitabinenab-paclitaxelvismodegib
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)SMO (Smoothened)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + nab-paclitaxel + vismodegib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + nab-paclitaxel + vismodegib.